CleveXel Pharma is a pharmaceutical company specialized in the design and early development of treatments providing innovative solutions to unmet patient needs.
Today we are focusing on two projects with recognized mechanisms of action on key pathophysiological processes and a mode of administration, dosage form or combination of effects that make them suitable and effective treatments for targeted pathologies.
With our joint expertise in drug development, we have solid assets to take these two high-potential projects, together with our partners, to clinical proof of concept, an important stage in value creation.
CleveXel has a portfolio of projects, at different stages of development, offering unique combinations of action mechanisms or original galenic approaches to address unmet needs such as:
- the reduction, by a topically administered antiradical agent, of mucositis or dermatitis, a major adverse effect of radiotherapy or chemotherapy (CVXL-0095),
- an action on B and T cells, involved in both the initiation and amplification of immuno-inflammatory processes through the inhibition of the key enzymes SYK and JAK (CVXL-0255)